JavaScript is off. Please enable to view full site.

Japanese biotech firm uses tiny worms in test for pancreatic cancer

Japanese biotech firm uses tiny worms in test for pancreatic cancer

Wednesday, November 30, 2022, 16:06 GMT+7
Japanese biotech firm uses tiny worms in test for pancreatic cancer
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

A Japanese biotech firm says it has developed the world's first early screening test for pancreatic cancer, using the powerful noses of tiny worms.

Hirotsu Bio Science this month launched its N-NOSE plus Pancreas test, marketing directly to consumers in Japan and with aims to bring the test to the United States by 2023.

Users send a urine sample through a special mail pouch to a lab, where it is put in a petri dish with a species of nematodes.

The creatures, known scientifically as C. elegans, have olfactory senses much more powerful than dogs, the company says, and they follow their nose toward cancer cells.

Nematodes are seen on a monitor connected to a microscope during a photo opportunity at the lab of Hirotsu Bio Science in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Nematodes are seen on a monitor connected to a microscope during a photo opportunity at the lab of Hirotsu Bio Science in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

That makes the 1-milimetre long animals a potent diagnostic tool, says company founder and chief executive Takaaki Hirotsu, who has been researching them for 28 years.

"What's very important with early detection of cancer and these kinds of diseases is being able to sense very trace amounts," Hirotsu told Reuters.

"And when it comes to that, I think that machines don't stand a chance against the capabilities that living organisms have."

Hirotsu Bio launched its first N-NOSE consumer test in January 2020 which claimed the ability to tell if users were at high risk of cancer or not. About 250,000 people have taken the original test, with about 5%-6% getting high-risk readings.

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

In the latest version, the company tweaked the genetic code of the nematodes so that they would swim away from pancreatic cancer samples. Hirotsu Bio started with pancreatic cancer due to its difficulty in diagnosis and speed of progression.

In the coming years, the company expects to roll out targeted tests for liver cancer, as well as cervical and breast cancers.

The pancreas test kit costs up to 70,000 yen ($505), comparatively expensive for a diagnostic test in Japan, which has a nationalised health care system and fixed prices for drugs and procedures.

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio poses with nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio poses with nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

The price tag, along with a TV ads using caricatures of the worms and the pancreas, are part of the process of building a brand, Hirotsu said, adding that the price may come down as the company scales up.

Some doctors have criticised this direct approach to consumers and doubted the medical usefulness of the results.

Masahiro Kami, the head of the Medical Governance Research Institute think tank in Tokyo, said that false positives could greatly outnumber actual cases of pancreatic cancer, making the results "not usable".

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

The company counters that the accuracy of N-NOSE stands up well against other diagnostic tests and are intended as early screening tools that can guide patients to further testing and treatment sooner.

Although he's been studying nematodes for decades and they form the basis of his company, Hirotsu says he doesn't have any particular affinity for the creatures.

"I feel like I have to give the answer that I love nematodes and I find them cute, but that's not the case at all," he said. Really, I just think of them as research materials and nothing more."

A Japanese biotech firm says it has developed the world's first early screening test for pancreatic cancer, using the powerful noses of tiny worms.

Hirotsu Bio Science this month launched its N-NOSE plus Pancreas test, marketing directly to consumers in Japan and with aims to bring the test to the United States by 2023.

Users send a urine sample through a special mail pouch to a lab, where it is put in a petri dish with a species of nematodes.

The creatures, known scientifically as C. elegans, have olfactory senses much more powerful than dogs, the company says, and they follow their nose toward cancer cells.

Nematodes are seen on a monitor connected to a microscope during a photo opportunity at the lab of Hirotsu Bio Science in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Nematodes are seen on a monitor connected to a microscope during a photo opportunity at the lab of Hirotsu Bio Science in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

That makes the 1-milimetre long animals a potent diagnostic tool, says company founder and chief executive Takaaki Hirotsu, who has been researching them for 28 years.

"What's very important with early detection of cancer and these kinds of diseases is being able to sense very trace amounts," Hirotsu told Reuters.

"And when it comes to that, I think that machines don't stand a chance against the capabilities that living organisms have."

Hirotsu Bio launched its first N-NOSE consumer test in January 2020 which claimed the ability to tell if users were at high risk of cancer or not. About 250,000 people have taken the original test, with about 5%-6% getting high-risk readings.

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

In the latest version, the company tweaked the genetic code of the nematodes so that they would swim away from pancreatic cancer samples. Hirotsu Bio started with pancreatic cancer due to its difficulty in diagnosis and speed of progression.

In the coming years, the company expects to roll out targeted tests for liver cancer, as well as cervical and breast cancers.

The pancreas test kit costs up to 70,000 yen ($505), comparatively expensive for a diagnostic test in Japan, which has a nationalised health care system and fixed prices for drugs and procedures.

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio poses with nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio poses with nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

The price tag, along with a TV ads using caricatures of the worms and the pancreas, are part of the process of building a brand, Hirotsu said, adding that the price may come down as the company scales up.

Some doctors have criticised this direct approach to consumers and doubted the medical usefulness of the results.

Masahiro Kami, the head of the Medical Governance Research Institute think tank in Tokyo, said that false positives could greatly outnumber actual cases of pancreatic cancer, making the results "not usable".

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters
Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. Photo: Reuters

The company counters that the accuracy of N-NOSE stands up well against other diagnostic tests and are intended as early screening tools that can guide patients to further testing and treatment sooner.

Although he's been studying nematodes for decades and they form the basis of his company, Hirotsu says he doesn't have any particular affinity for the creatures.

"I feel like I have to give the answer that I love nematodes and I find them cute, but that's not the case at all," he said. Really, I just think of them as research materials and nothing more."

Reuters

More

Read more

ChatGPT sets record for fastest-growing user base: analyst note

ChatGPT, the popular chatbot from OpenAI, is estimated to have reached 100 million monthly active users in January, just two months after launch, making it the fastest-growing consumer application in history, according to a UBS study on Wednesday

20 hours ago

Missing radioactive capsule found in Western Australia

Australian authorities on Wednesday found a radioactive capsule that was lost in the vast Outback after nearly a week-long search along a 1,400 km (870-mile) stretch of highway, an emergency services official said

1 day ago
;

Photos

VIDEOS

‘Taste of Australia’ gala dinner held in Ho Chi Minh City after 2-year hiatus

Taste of Australia Gala Reception has returned to the Park Hyatt Hotel in Ho Chi Minh City's District 1 after a two-year hiatus due to the COVID-19 pandemic

Vietnamese woman gives unconditional love to hundreds of adopted children

Despite her own immense hardship, she has taken in and cared for hundreds of orphans over the past three decades.

Vietnam’s Mekong Delta celebrates spring with ‘hat boi’ performances

The art form is so popular that it attracts people from all ages in the Mekong Delta

Vietnamese youngster travels back in time with clay miniatures

Each work is a scene caught by Dung and kept in his memories through his journeys across Vietnam

Latest news